{"created":"2023-05-15T09:45:53.494737+00:00","id":7183,"links":{},"metadata":{"_buckets":{"deposit":"2d7ba883-9e43-48b7-b6e9-88577b0f90ad"},"_deposit":{"created_by":11,"id":"7183","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"7183"},"status":"published"},"_oai":{"id":"oai:kagawa-u.repo.nii.ac.jp:00007183","sets":["13:40"]},"author_link":["3075"],"item_10006_alternative_title_1":{"attribute_name":"その他（別言語等）のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"形質細胞腫瘍に対するがん治療用HSV-1とレナリドミドの併用療法","subitem_alternative_title_language":"ja"}]},"item_10006_date_granted_11":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2020-12-24"}]},"item_10006_degree_grantor_9":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"香川大学"},{"subitem_degreegrantor_language":"en","subitem_degreegrantor_name":"Kagawa University"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"16201","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_10006_degree_name_8":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_10006_description_7":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Oncolytic viruses exert an anti-tumour effect through two mechanisms: direct oncolytic and indirect immune-mediated mechanisms. Although oncolytic herpes simplex virus type 1 (HSV-1) has been approved for melanoma treatment and is being examined for its applicability to a broad spectrum of malignancies, it is not known whether it has an anti-myeloma effect. In the present study, we show that the third-generation oncolytic HSV-1, T-01, had a direct oncolytic effect on five of six human myeloma cell lines in vitro. The anti-tumour effect was enhanced in the presence of peripheral blood mononuclear cells (PBMCs) from healthy individuals and, to a lesser extent, from patients with myeloma. The enhancing effect of PBMCs was abrogated by blocking type I interferons (IFNs) or by depleting plasmacytoid dendritic cells (pDCs) or natural killer (NK) cells, suggesting that pDC-derived type I IFNs and NK cells dominated the anti-tumour effect. Furthermore, the combination of T-01 and lenalidomide exhibited enhanced cytotoxicity, and the triple combination of T-01, lenalidomide and IFN-α had a maximal effect. These data indicate that oncolytic HSV-1 represents a viable therapy for plasma cell neoplasms through direct oncolysis and immune activation governed by pDCs and NK cells. Lenalidomide is likely to augment the anti-myeloma effect of HSV-1.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10006_dissertation_number_12":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"甲第758号"}]},"item_10006_relation_15":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1111/bjh.17173","subitem_relation_type_select":"DOI"}}]},"item_10006_relation_22":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"33216988","subitem_relation_type_select":"PMID"}}]},"item_10006_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright © 2020 British Society for Haematology and John Wiley & Sons Ltd.","subitem_rights_language":"en"},{"subitem_rights":"Embergo expiration date: 2021-11-20","subitem_rights_language":"en"},{"subitem_rights":"This is the Accepted Version of the following article: Oncolytic herpes simplex virus type 1 (HSV‐1) in combination with lenalidomide for plasma cell neoplasms; British journal of haematology; Volume 192 Number 2 (2020）) Pages: 343-353; doi: 10.1111/bjh.17173, which has been published in final form at https://doi.org/10.1111/bjh.17173.\t","subitem_rights_language":"en"}]},"item_10006_text_29":{"attribute_name":"WAID","attribute_value_mlt":[{"subitem_text_value":"3075"}]},"item_10006_text_30":{"attribute_name":"KEID","attribute_value_mlt":[{"subitem_text_value":"29141"}]},"item_10006_version_type_18":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_fa2ee174bc00049f","subitem_version_type":"P"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationName":"","affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"Oku, Maki","creatorNameLang":"en"},{"creatorName":"奥, 真紀","creatorNameLang":"ja"},{"creatorName":"オク, マキ","creatorNameLang":"ja-Kana"}],"familyNames":[{"familyName":"Oku","familyNameLang":"en"},{"familyName":"奥","familyNameLang":"ja"},{"familyName":"オク","familyNameLang":"ja-Kana"}],"givenNames":[{"givenName":"Maki","givenNameLang":"en"},{"givenName":"真紀","givenNameLang":"ja"},{"givenName":"マキ","givenNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"3075","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-11-20"}],"displaytype":"detail","filename":"Med_A758.pdf","filesize":[{"value":"791.5 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"本文","objectType":"fulltext","url":"https://kagawa-u.repo.nii.ac.jp/record/7183/files/Med_A758.pdf"},"version_id":"223c3ab1-c2e0-49dd-b01c-a8e034e5baf5"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-02-03"}],"displaytype":"detail","filename":"Med_A758_abstract.pdf","filesize":[{"value":"83.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"内容の要旨","objectType":"abstract","url":"https://kagawa-u.repo.nii.ac.jp/record/7183/files/Med_A758_abstract.pdf"},"version_id":"f5e88eb1-2b9f-4888-a366-70992f70ce91"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-02-03"}],"displaytype":"detail","filename":"Med_A758_result.pdf","filesize":[{"value":"57.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"審査の結果の要旨","objectType":"other","url":"https://kagawa-u.repo.nii.ac.jp/record/7183/files/Med_A758_result.pdf"},"version_id":"f7096ccd-8219-44c9-b63b-3d76fb1c8102"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"myeloma","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"oncolytic virus","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"HSV‐1","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"lenalidomide","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"immunotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Oncolytic HSV-1 in combination with lenalidomide for plasma cell neoplasms","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Oncolytic HSV-1 in combination with lenalidomide for plasma cell neoplasms","subitem_title_language":"en"}]},"item_type_id":"10006","owner":"11","path":["40"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-02-03"},"publish_date":"2021-02-03","publish_status":"0","recid":"7183","relation_version_is_last":true,"title":["Oncolytic HSV-1 in combination with lenalidomide for plasma cell neoplasms"],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2024-10-31T08:01:28.513977+00:00"}